Is Staphylococcus saprophyticus a common cause of urinary tract infections (UTIs), especially in younger, sexually active women?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 21, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Is Staphylococcus saprophyticus a Common UTI Bacteria?

Yes, Staphylococcus saprophyticus is a common cause of UTIs, ranking as the second most frequent pathogen after E. coli in young, sexually active women, accounting for approximately 10-11% of all UTIs in this specific population. 1, 2, 3

Epidemiological Context

S. saprophyticus occupies a distinct niche in UTI microbiology:

  • E. coli remains the dominant pathogen, causing approximately 75% of recurrent UTIs across all patient groups 1, 4
  • S. saprophyticus is definitively the second most common cause of uncomplicated UTIs specifically in young, sexually active women, representing 10-11% of cases in this demographic 2, 5, 3
  • The organism is listed among the "most other infections" after E. coli, alongside Enterococcus faecalis, Proteus mirabilis, and Klebsiella, particularly in patients with risk factors for complicated UTIs 1

Key Population Characteristics

The typical patient profile for S. saprophyticus UTI is highly specific:

  • Mean age of infected patients is approximately 20-32 years 2, 6
  • 83.9% of infections occur in women aged 15-44 years, including pregnant women 6
  • The organism is rarely found in men (only 7 out of 331 cases in one 10-year study) 6
  • Sexual activity is a major risk factor, with the organism showing pathogenesis similar to E. coli UTIs 3, 7

Seasonal and Clinical Patterns

S. saprophyticus demonstrates unique epidemiological features:

  • Infections peak during late summer and early fall (particularly June and November) 6, 3
  • Most cases present as acute cystitis, though frank pyelonephritis can occur 2
  • 41% of infections may localize to the upper urinary tract (compared to 16% for E. coli), suggesting more aggressive behavior 3
  • The organism is rarely found as a contaminant in urine cultures, making its presence clinically significant 2

Risk Factors

Specific exposures increase S. saprophyticus UTI risk:

  • Spermicide-coated condom use is strongly associated with infection (OR 8.4-10.9 for frequent use), with 74% of S. saprophyticus UTIs attributable to this exposure among exposed women 7
  • Younger age, higher intercourse frequency, and prior UTI history are independent predictors 7
  • Mucocutaneous colonization (rectal, vaginal, urethral) with S. saprophyticus significantly associates with subsequent UTI 3

Clinical Significance

Important considerations for practice:

  • The organism should be accepted as an important urinary tract pathogen in young female patients, not dismissed as a contaminant 2
  • Signs, symptoms, and urinalysis findings are similar to E. coli infections, making clinical differentiation impossible without culture 3
  • Recurrent infections can occur despite adequate therapy in some patients 3
  • While rare, complicated UTIs including renal abscess can occur even in immunocompetent hosts without traditional risk factors 5

Common Pitfall to Avoid

Do not dismiss S. saprophyticus as skin flora contamination when isolated from urine cultures in young women—it is rarely a contaminant and represents true infection requiring treatment 2. The organism's presence should prompt consideration of spermicide exposure and counseling about alternative contraceptive methods 7.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.